Ashwagandha safety check in seniors: small study ends early

NCT ID NCT06171724

Terminated Knowledge-focused Sponsor: Oregon Health and Science University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study aimed to measure how a standardized ashwagandha supplement is absorbed and tolerated in healthy adults aged 65 and older. Eleven participants took either 240 or 480 mg of the supplement, and researchers tracked levels of active compounds in the blood over 48 hours. The study was terminated early, so the findings are limited to basic safety and absorption data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ashwagandha (Withania somnifera) extract
What this could lead to: If successful, this could provide basic information on how ashwagandha is absorbed and tolerated in older adults, potentially guiding future studies on its health effects.
What could go wrong: This was a very small, early-phase study that was terminated, so results are limited. It only looked at safety and absorption, not whether ashwagandha has any health benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGING HEALTHY

Contacts and locations

Locations

Oregon Health & Science University

Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.